Mucosal microbiotas and their role in stem cell transplantation

Ingham, Anna Cäcilia; Pamp, Sünje Johanna

doi:10.1111/apm.13208

Cited by 4 publications

(4 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 49 These differences might be important, since SCFAs are known modulators of inflammation. 50 On the one hand, an initial shift in SCFA-producing bacterial abundances might promote inflammation and thereby the progression of PV. In contrast, PV-associated inflammation might contribute to impaired growth conditions for certain SCFA producers in the gut.…”

Section: Discussionmentioning

confidence: 99%

The gut microbiota in patients with polycythemia vera is distinct from that of healthy controls and varies by treatment

et al. 2023

Self Cite

View full text Add to dashboard Cite

Chronic inflammation is believed to play an important role in the development and disease progression of polycythemia vera (PV). Since an association between gut microbiota, hematopoiesis, and inflammation is well established we hypothesized that patients with PV have a gut microbiota distinct from healthy controls. Recombinant interferon-α2 (IFN) treatment of patients with PV has been shown to be disease-modifying in terms of normalization of elevated blood cell counts in concert with a reduction in the JAK2V617F allelic burden. Therefore, we hypothesized that patients treated with IFN might have a composition of the gut microbiota towards normalization. Herein, via amplicon-based next generation sequencing of the V3-V4 regions of the 16S rRNA gene, we report on an abnormal gut microbiota in 102 patients with PV as compared with 42 healthy controls (HCs). Patients with PV had a lower alpha diversity and a lower relative abundance of several taxa belonging to Firmicutes (45%) compared with HCs (59%, p<0.001). Furthermore, we report the composition of the gut microbiota to differ between the treatment groups (IFN, hydroxyurea, no treatment, combination therapy with IFN and ruxolitinib) and the HCs. The observations are highly interesting considering the potential pathogenetic importance of an altered gut microbiota for development of other diseases, including chronic inflammatory diseases. Our observations call for further gut microbiota studies to decipher potential causal associations between treatment and the gut microbiota in PV and related neoplasms.

show abstract

Section: Discussionmentioning

confidence: 99%

The gut microbiota in patients with polycythemia vera is distinct from that of healthy controls and varies by treatment

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…34 Taxa within the Firmicutes phylum, especially F. prausnitzii, are essential producers of butyrate and other anti-inflammatory metabolites. [35][36][37] Butyrate is a well-known modulator of inflammation and is important in regulating the gut barrier integrity and permeability, 38,39 and a link between damaged intestinal barrier and AML progression, due to increased inflammation, has been proposed. 34 The low relative abundance of Faecalibacterium across the entire biological continuum of sub-diagnoses, regardless of mutation, diagnosis, and allele burden is therefore highly intriguing, especially as chronic inflammation is considered a major driver of the development and disease progression in MPN.…”

Section: Discussionmentioning

confidence: 99%

JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms

Eickhardt‐Dalbøge,

Nielsen,

Fuursted

et al. 2024

European J of Haematology

Self Cite

View full text Add to dashboard Cite

BackgroundEssential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (MF) are myeloproliferative neoplasms (MPN). Inflammation is involved in the initiation, progression, and symptomology of the diseases. The gut microbiota impacts the immune system, infection control, and steady‐state hematopoiesis.MethodsWe analyzed the gut microbiota of 227 MPN patients and healthy controls (HCs) using next‐generation sequencing. We expanded our previous results in PV and ET patients with additional PV, pre‐MF, and MF patients which allowed us to compare MPN patients collectively, MPN sub‐diagnoses, and MPN mutations (separately and combined) vs. HCs (N = 42) and compare within MPN sub‐diagnoses and MPN mutation.ResultsMPN patients had a higher observed richness (median, 245 [range, 49–659]) compared with HCs (191.5 [range, 111–300; p = .003]) and a lower relative abundance of taxa within the Firmicutes phylum; for example, Faecalibacterium (6% vs. 14%, p < .001). The microbiota of CALR‐positive patients (N = 30) resembled that of HCs more than that of patients with JAK2V617F (N = 177). In JAK2V617F‐positive patients, only minor differences in the gut microbiota were observed between MPN sub‐diagnoses, illustrating the importance of this mutation.ConclusionThe gut microbiota in MPN patients differs from HCs and is driven by JAK2V617F, whereas the gut microbiota in CALR patients resembles HCs more.

show abstract

“… Bacterial strains used in probiotic therapy (based on [ 112 , 122 , 123 , 124 , 125 , 126 , 127 , 128 , 129 , 130 , 131 , 132 , 133 ]). …”

Section: Gut Microbiome—probiotics Prebiotics Faecal Microbiota Trans...mentioning

confidence: 99%

“…Figure 2. Bacterial strains used in probiotic therapy (based on[112,[122][123][124][125][126][127][128][129][130][131][132][133]). …”

mentioning

confidence: 99%

The Critical Exploration into Current Evidence behind the Role of the Nutritional Support in Adult Patients Who Undergo Haematogenic Stem Cell Transplantation

et al. 2023

View full text Add to dashboard Cite

Haematopoietic stem cell transplantation (HSCT) is a treatment option for many haematological conditions in patients of all ages. Nutritional support is important at each stage of treatment, but particular nutritional needs and dictated support occur during the preparatory (conditioning regimen) and post-transplant periods. Patients may require nutritional treatment by the enteral or parenteral route. The quantitative and qualitative composition of meals may change. Vitamin requirements, including vitamin D and vitamin C, might also be different. An adequately composed diet, adapted to the needs of the patient, may influence the occurrence of complications such as graft-versus-host disease (GvHD), gastrointestinal disorders, infections, and reduced survival time. Haematological diseases as well as transplantation can negatively affect the intestinal flora, with negative consequences in the form of mucosal inflammation and disorders of a functional nature. Currently, aspects related to nutrition are crucial in the care of patients after HSCT, and numerous studies, including randomized trials on these aspects, are being conducted. This study serves the critical analysis of current scientific evidence regarding nutritional support for patients after HSCT.

show abstract

Mucosal microbiotas and their role in stem cell transplantation

Cited by 4 publications

References 80 publications

The gut microbiota in patients with polycythemia vera is distinct from that of healthy controls and varies by treatment

The gut microbiota in patients with polycythemia vera is distinct from that of healthy controls and varies by treatment

JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms

The Critical Exploration into Current Evidence behind the Role of the Nutritional Support in Adult Patients Who Undergo Haematogenic Stem Cell Transplantation

Contact Info

Product

Resources

About